System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 40225701 DOI: 10.2147/CEOR.S501404

Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma.

Clinicoecon Outcomes Res 17:289-302

Authors: Bhavesh Shah, Rickard Sandin, Yun Liu, Laura R Bobolts, Yannan Hu, Isha Mol, Alexander Schepart, David M Hughes, Jim Hart, Patrick Hlavacek

Affiliations

  • Boston Medical Center, Boston, MA, USA.
  • Pfizer AB, Stockholm, Sweden.
  • Cytel, Rotterdam, Netherlands.
  • Oncohealth, Pompano Beach, FL, USA.
  • Pfizer Inc, New York, NY, USA.

Abstract

Purpose

To estimate the budget impact of adding elranatamab to the US formulary to treat adults with RRMM who have received ≥4 prior lines of therapy including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody, and to assess the total cost of care and cost per month of progression-free survival (PFS) between elranatamab and available treatments.

Methods

An economic model was developed to assess the budget impact of elranatamab in a one-million-member US commercial and Medicare health plan. Epidemiology data was obtained from the SEER database and a large US real-world study. Key clinical inputs included treatment duration, PFS, overall survival, and adverse events (AEs). Costs associated with drug acquisition monitoring, medical resource use (specifically hospitalization and physician visits), and AEs were incorporated. Model inputs were sourced from clinical trial data, US government databases, and published literature. Total budget impact and per member per month (PMPM) were assessed. One-way sensitivity analyses (OWSA) were conducted to assess model input uncertainty. Total cost of care and cost per month of PFS were also assessed.

Results

An estimated 14 (commercial) and 60 (Medicare) RRMM patients per year would be eligible for treatment. Adding elranatamab resulted in a total budget impact of 553,607 (0.05 PMPM) in commercial and 2,351,515 (0.20 PMPM) in Medicare over three years. OWSA indicated results were most sensitive for elranatamab drug costs and relative dose intensity. Total cost of care per month of median PFS over one year was 19,642 with elranatamab, talquetamab (33,391), teclistamab (37,791), selinexor plus dexamethasone (48,784), physician's choice of treatment (65,886), idecabtagene vicleucel (78,361), and ciltacabtagene autoleucel (17,640).

Conclusion

Elranatamab for RRMM is projected to result in a minimal to small budget impact over 3 years and good economic value with lower cost of care per month of PFS compared with other available RRMM treatments except for ciltacabtagene autoleucel.

MeSH

Pharmaceutical Preparations, Medicare, Multiple Myeloma, Physicians, Budgets, Therapeutics

Cited by